friends-using-mobile-phone_1048944-27475336-transformed

WHAT HAPPENED TO MDMA AT THE FDA LAST WEEK?

NPR is a good source for news on the progress of psychedelics for some mental health concerns.  Early June 2024 saw the advisors for the FDA reject use of MDMA (Ecstasy) as a treatment for Post-Traumatic Stress Disorder (PTSD).  MDMA has been seen to show great promise to the Veteran community as a treatment for PTSD.  It should be noted, although not likely, that the FDA may still approve MDMA at some level for the treatment of PTSD.

Concerns that lead to the rejection by the advisory centered around the methods and data bias they found in the study.

Read more detail regarding the state of approval (or lack thereof) of MDMA by the FDA here:

Will MDMA’s FDA setback derail psychedelic drug research? : Shots – Health News : NPR

therapy for young adult

OREGON PSILOCYBIN INDUSTRY SEEING A REDUCED CUSTOMER BASE

Oregon Public Broadcasting is reporting a decline in the Psilocybin industry in Oregon based on a few causes.  Some of them include advertising restrictions, increased competition among service centers and facilitators (high or no limit on the number of licenses issued) and more.

California is using Oregon as a model for new legislation regarding the therapeutic use of Psilocybin for mental health issues.  JT hopes that some of the lessons learned in Oregon will be addressed in the legislation.  Specifically, the efforts by Oregon to take the therapy out of the program.  It is our experience that the experience in Oregon can be life altering in a very positive way however, the integration is sorely lacking and even leaves clients feeling abandoned by the experience.  It is critical to the health and progress for our clients that integration take the time and effort necessary to help the client understand their journey and, perhaps more importantly, what to do with that newfound information.

Oregon’s psilocybin industry, a year old, seeks customers – OPB